Today: 19 January 2026
Subscribe
Browse Category

Healthcare Innovation News 8 October 2025 - 3 November 2025

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income Simplywall. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 Tipranks, and free cash flow turning positive in 2025 Simplywall. These forecasts assume continued momentum in weight-loss/metabolic services plus…
3 November 2025
·
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicine Stockanalysis. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon…
3 November 2025
···
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) Stockanalysis. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech Stockanalysis after the company announced the Chugai collaboration and financing. Even after that…
31 October 2025
···
From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

Market Analysis & Forecast: For now, analysts and investors appear in “wait and see” mode. Near-term catalysts will be pivotal. These include the finalization (or not) of the Antalpha $250M convertible deal – which would inject capital but on what terms? – and the company’s next earnings report (to show if core healthcare revenue is growing or still minuscule). If…
28 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coverage Contractpharma Gxpnews; GxP News Gxpnews Gxpnews; The Medicine Maker/Conexiant Conexiant Conexiant; GlobeNewswire (Hengdian/Apeloa) Globenewswire; Evaluate Pharma forecast Evaluate Evaluate; Reuters Reuters; TechStock² / TS2 Tech ts2.tech ts2.tech; TS2 Tech ts2.tech ts2.tech.…
28 October 2025
···
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in…
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test Samsung Tradingview. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” Samsung. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic…
18 October 2025
····
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination Globenewswire Stocktitan. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc…
16 October 2025
···
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 Renaissancecapital. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listing Stockanalysis. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatments Benzinga. CEO Bradley…
9 October 2025
····
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Company Overview and Mission Tempus AI, Inc. is an American health technology company founded in 2015 by entrepreneur Eric Lefkofsky (best known as co-founder of Groupon). Headquartered in Chicago, Tempus was born from Lefkofsky’s personal mission to improve cancer care after his wife’s battle with breast cancer Wikipedia. The company’s core focus is on applying AI and data analytics to personalized medicine. Tempus has built…
8 October 2025
····
1 2

Stock Market Today

  • KeyCorp Announces $0.205 Dividend with Cautious Outlook on Sustainability
    January 19, 2026, 8:07 AM EST. KeyCorp (NYSE:KEY) will pay a dividend of $0.205 per share on March 13, representing a 3.9% yield above the industry average. The bank has a decade-long history of dividend payments, growing at 11% annually from $0.30 in 2016 to $0.82 recently. However, its payout ratio is high at 94%, raising concerns about sustainability despite forecasted earnings per share growth of 147% over three years and an expected payout ratio drop to 43%. Earnings have declined 5.7% annually over five years, adding to uncertainty. Analysts urge caution as KeyCorp's dividend payments may be challenging to maintain, though past consistency offers some reassurance.
Go toTop